1Perrillo R,Hann HW,Mutimer D,et al.Adefovir dipivoxiladded to ongoing lamivudine in chronic hepatitis B with YMDDmutant hepatitis B virus mutant[].Gastroenterology.2004
2Hsu YS,Chien RN,Yeh CT,et al.Long-term outcome afterspontaneous HBeAg seroconversion in patients with chronichepatitis B[].Hepatology.2002
3Chu CM,Hung SJ,Lin J,et al.Natural history of hepatitisB e antigen to antibody seroconversion in patients with normalserum aminotransferase levels[].The American Journal of Medicine.2004
4Lok ASF,McMahon BJ.Chronic hepatitis B:update of rec-ommendation[].Hepatology.2004
5Hadziyannis S,Tassopoulos N,Chang TT,et al.Three yearstudy of adefovir dipivoxil(ADV)demonstrates sustained effi-cacy in presumed precore mutant chronic hepatitis B(CHB)patients in a long term safety and efficacy study(LTSES)[].Journal of Hepatology.2004
6Liaw YF,Leung N,GuanR.Lau GKK and Merican I for theAsian Pacific Consensus working parties on hepatitis B.Asian-Pacific Consensus statement on the management of chronichepatitis B:An update[].Journal of Gastroenterology.2003
7Leung NW,Lai CL,Chang TT,et al.Extended lamivudinetreatment in patients with chronic hepatitis B enhances hepati-tis B e antigen seroconversion rates:results after 3 years oftherapy[].Hepatology.2001
3Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
